Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083954 · ClinicalTrials.gov registry record · Phase 3
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
NCT00083954 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 530 participants.
The verdict
NCT00083954, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of quetiapine compared to placebo in the treatment for a major depressive episode in patients with bipolar disorder after receiving treatment for up to 8 weeks.
Interventions
- DRUG Quetiapine Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083954
The ClinicalTrials.gov registry entry for NCT00083954 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quetiapine Fumarate is the first listed.
NCT00083954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083954 about?
NCT00083954 is a clinical study titled "Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression". The purpose of this study is to determine the efficacy of quetiapine compared to placebo in the treatment for a major depressive episode in patients with bipolar disorder after receiving treatment for up to 8 weeks.
What is the current status of trial NCT00083954?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2004-06. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00083954?
The interventions under investigation include: Quetiapine Fumarate (DRUG).
Who is sponsoring clinical trial NCT00083954?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.